VMT treatment recommended in NICE FAD

Sep 12, 2013

The UK's National Institute for Health and Care Excellence (NICE) has confirmed in its Final Appraisal Determination (FAD) that JETREA (Ocriplasmin: ThromboGenics, Leuven, Belgium) is an innovative new treatment and should be reimbursed in the National Health Service (NHS).

The UK's National Institute for Health and Care Excellence (NICE) has confirmed in its Final Appraisal Determination (FAD) that JETREA (Ocriplasmin: ThromboGenics, Leuven, Belgium) is an innovative new treatment and should be reimbursed in the National Health Service (NHS).

This announcement confirms the earlier appraisal consultation document released by the regulatory body that initially recommended the treatment as an option for adults suffering from vitreomacular traction (VMT). This indication included those patients suffering from VMT associated with macular hole less that or equal to 400 microns in addition to those with severe symptoms and an epiretinal membrane is not present.

"This further endorsement from UK NICE is great news for ensuring that physicians, who are treating patients with VMT and macular hole, will have access to JETREA, the first and only pharmaceutical treatment for this progressive disease," said Dr Patrik De Haes, CEO of ThromboGenics. "There is growing evidence that prolonged VMT may lead to progressive loss of vision and increase a risk that subsequent intervention may be less successful… We look forward to final NICE guidance later this year."

More information on this may be found at the company’s website: www.thrombogenics.com